Research Analysts Set Expectations for ACRS FY2025 Earnings

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Analysts at Leerink Partnrs lowered their FY2025 earnings estimates for Aclaris Therapeutics in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now forecasts that the biotechnology company will earn ($0.61) per share for the year, down from their prior forecast of ($0.45). Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.86) per share. Leerink Partnrs also issued estimates for Aclaris Therapeutics’ FY2026 earnings at ($0.74) EPS, FY2027 earnings at ($0.89) EPS and FY2028 earnings at ($1.19) EPS.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.03). The business had revenue of $4.35 million during the quarter, compared to analysts’ expectations of $8.31 million. Aclaris Therapeutics had a negative return on equity of 40.26% and a negative net margin of 136.65%.

Several other analysts have also recently issued reports on ACRS. StockNews.com cut Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Cantor Fitzgerald raised Aclaris Therapeutics to a “strong-buy” rating in a research report on Thursday, January 30th. Leerink Partners upgraded shares of Aclaris Therapeutics from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $2.00 to $7.00 in a report on Tuesday, November 19th. Jefferies Financial Group upgraded shares of Aclaris Therapeutics from a “hold” rating to a “buy” rating and raised their price target for the company from $2.00 to $7.00 in a report on Tuesday, November 19th. Finally, BTIG Research upgraded shares of Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $8.00 price objective for the company in a research note on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, five have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $11.00.

Aclaris Therapeutics Stock Up 2.5 %

Shares of ACRS stock opened at $2.49 on Friday. The firm has a market cap of $177.86 million, a price-to-earnings ratio of -4.79 and a beta of 0.50. Aclaris Therapeutics has a 52-week low of $0.95 and a 52-week high of $5.17. The company’s 50 day moving average is $2.85 and its 200 day moving average is $2.05.

Insider Transactions at Aclaris Therapeutics

In related news, Director Anand Mehra acquired 666,666 shares of the stock in a transaction dated Tuesday, November 19th. The stock was acquired at an average cost of $2.25 per share, for a total transaction of $1,499,998.50. Following the completion of the purchase, the director now owns 710,030 shares of the company’s stock, valued at approximately $1,597,567.50. This represents a 1,537.37 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 6.40% of the company’s stock.

Hedge Funds Weigh In On Aclaris Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ACRS. Millennium Management LLC increased its holdings in shares of Aclaris Therapeutics by 1.9% in the second quarter. Millennium Management LLC now owns 3,336,850 shares of the biotechnology company’s stock valued at $3,671,000 after purchasing an additional 63,358 shares during the period. Assenagon Asset Management S.A. acquired a new position in Aclaris Therapeutics in the 3rd quarter worth approximately $214,000. BML Capital Management LLC increased its holdings in Aclaris Therapeutics by 9.7% in the 3rd quarter. BML Capital Management LLC now owns 14,250,000 shares of the biotechnology company’s stock worth $16,388,000 after buying an additional 1,261,866 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its position in Aclaris Therapeutics by 187.6% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 332,406 shares of the biotechnology company’s stock worth $382,000 after buying an additional 216,826 shares during the last quarter. Finally, Stonepine Capital Management LLC lifted its stake in Aclaris Therapeutics by 27.6% during the 3rd quarter. Stonepine Capital Management LLC now owns 2,458,873 shares of the biotechnology company’s stock valued at $2,828,000 after acquiring an additional 531,427 shares during the period. Hedge funds and other institutional investors own 98.34% of the company’s stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.